









Active substances set

Search phrase: Liver cancer

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Liver cancer

Regorafenib	Regorafenib jest wskazany w monoterapii do leczenia dorosłych pacjentów z rakiem wątrobowokomórkowym (ang. hepatocellular carcinoma, HCC), którzy wcześniej byli leczeni sorafenibem.	 NO REIMBURSEMENT  ESMO
Lenvatinib	Lenvatinib w monoterapii jest wskazany w leczeniu dorosłych pacjentów z zaawansowanym lub nieoperacyjnym rakiem wątrobowokomórkowym, którzy nie byli poddani wcześniej leczeniu ogólnemu.	 NO REIMBURSEMENT  ESMO
Ramucirumab	Ramucirumab monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.	 NO REIMBURSEMENT  ESMO
Pembrolizumab	Pembrolizumab, in combination with gemcitabine and cisplatin, is indicated for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma (BTC) in adults. Pembrolizumab as monotherapy is indicated for the treatment of the following microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.	 NO REIMBURSEMENT  ESMO

Cabozantinib

Cabozantinib is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.

 **REIMBURSEMENT
WITH RESTRICTIONS**

 **ESMO**

Atezolizumab

Atezolizumab, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

 **FULL
REIMBURSEMENT**

 **ESMO**

Durvalumab

Biliary Tract Cancer (BTC) Durvalumab in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer (BTC). Hepatocellular Carcinoma (HCC) Durvalumab as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Durvalumab in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

 **FULL
REIMBURSEMENT**

 **ESMO**